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O
ne of the key characteristics 
of retroviruses is their ability 
to integrate a copy of the 
DNA reverse-transcribed from their 
viral RNA genome into host cell 
DNA. This integration is mediated 
by a preintegration complex (PIC) 
comprising viral DNA, reverse 
transcriptase, and integrase, as well 
as poorly characterized host proteins 
[1]. It is this property that makes 
retroviruses good vectors for the 
transfer of therapeutic genes, and many 
such vectors have been made. 
Stages in Vector Development
Early vectors included those derived 
from murine oncoretroviruses (RVs) 
such as  murine leukemia virus (MLV). 
A limitation of these viruses was that 
their PIC requires that the nuclear 
membrane is dissolved so that the PIC 
can come in direct contact with host 
cell DNA; hence, there is efﬁ  cient 
integration only in dividing cells. Later 
vectors were based on lentiviruses (LVs) 
such as human immunodeﬁ  ciency virus 
and simian immunodeﬁ  ciency virus 
(SIV), whose PIC can penetrate into 
the nucleus so that integration can 
occur in nondividing cells that are in 
the G1 phase of the cell cycle. 
Insertional Mutagenesis
MLV-derived vectors have been used 
with success to achieve sustained 
correction of two forms of severe 
combined immunodeﬁ  ciency (SCID)—
SCID-X1 (Gamma-c deﬁ  ciency) [2] and 
adenosine deaminase deﬁ  ciency [3]. In 
both cases, hematopoietic progenitors 
were infected out of the patient’s 
body with nonreplicative MLV-derived 
vectors. However, integration carries 
the risk of insertional mutagenesis. 
This mutagenesis has been 
demonstrated in the chicken by using 
replicative RVs. RV integration close 
to protooncogenes has been shown 
to induce their activation, leading 
to tumorigenesis. Nonreplicative 
MLV vectors have also been reported 
to induce insertional mutagenesis 
in a murine model [4] and, more 
worryingly, in two patients from the 
SCID-X1 trial [5]. In both instances, it 
is suggested that cooperation between 
vector-associated transgene expression 
(dLNGFR in one case and common 
Gamma chain in the other) and long 
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terminal repeat–driven enhancement 
of protooncogene expression (evl-1 and 
LMO-2, respectively) was responsible 
for aberrant clonal proliferation. No 
such events have been reported yet in 
the use of LV vectors in experimental 
settings.
Sites of Retroviral Integration
It was initially believed that integration 
of retroviruses occurred randomly, but 
the advent of technology allowing the 
assessment of RV or LV integration 
into host cell genomes has led to a 
reassessment of this assumption. Using 
a combination of ligation-mediated 
polymerase chain reactions and 
sequencing of ampliﬁ  ed integration 
sites (unique sequences made from 
the viral long terminal repeat and the 
host-genome-associated sequence), 
it is possible to determine all the 
integration sites that can be found in a 
given transduced cell population (or its 
progeny). Exact mapping can be done 
back to the human (or relevant animal) 
genome database. However, even this 
methodology may not detect all of the 
integration sites present in a given 
transduced cell population.
Key papers have determined the 
“rules of the game” for RV and LV 
integration into a variety of cell lines 
[6,7,8]; these rules seem to differ 
between the virus types. In both cases, 
however, the integration pattern is 
not random. RV integration tends 
to be close to transcription start sites 
of active genes—close enough to 
regulatory sequences to potentially 
exert a long terminal repeat–mediated 
enhancer effect [7,8]. By contrast, 
LVs integrate mostly in transcription 
units, with a preference for actively 
transcribed genes, but do not 
target the region downstream of 
transcription start sites [6,8]. These 
data indicate that there are virus-
speciﬁ  c PIC-associated determinants 
that cause speciﬁ  c targeting with the 
host cell genome. However, much 
remains to be done to identify viral 
factors and host ligands involved in 
these interactions.
Data from these pioneering papers 
were obtained by in vitro infection 
of mature cells or cell lines with the 
relevant RV or LV [6,7,8]. However, 
it is possible that the pattern of 
integration might differ in other cell 
subsets, particularly immature cells 
such as hematopoietic progenitors. In 
fact, as shown by Mitchell et al. [8], 
infection of mature cells of different 
tissue types leads to a partially distinct 
pattern of integration sites related to 
the set of genes transcribed in these 
different cell types [8]. 
In Vivo Models
In a paper published in last month’s 
PLoS Biology, Hematti et al. [9] took 
the in vivo analysis further by analyzing 
the pattern of integration sites in cells 
derived from simian hematopoietic 
progenitor cells transduced either 
with a RV (MLV) or a LV (SIV) vector 
and transplanted into monkeys. This 
experimental setting is the closest 
possible to human trials. The results 
essentially conﬁ  rm the nonrandom 
insertion pattern of both types of 
vectors as shown by the analysis of cell 
lines transduced in vitro. The analysis 
showed the Gaussian distribution of 
insertions centered on the transcription 
start site—thus very close to regulatory 
elements—of RV (Figure 1), and the 
preference of LV for the transcription 
units, with a concentration of 
integrations into some gene-dense 
regions [9]. A study such as this is 
therefore a useful piece of preclinical 
work that will help the interpretation of 
the analysis of clinical samples. 
Similar data were also obtained 
by Laufs et al. in the analysis 
of a set of RV integration sites 
into human hematopoietic 
progenitors xenotransplanted into 
immunodeﬁ  cient mice [10]. It thus 
appears that the overall distinct pattern 
of RV and LV integration could be 
independent of transduced cell types 
(immature versus differentiated, and 
tissue type). However, the targeted 
genes could differ considerably 
depending on the set of genes 
expressed in the target cell. Several 
parameters could potentially inﬂ  uence 
the transcription proﬁ  le in a clinical 
setting, including stage of cell maturity, 
tissue type, ex vivo transduction culture 
conditions, patient age [5], underlying 
genetic disease, and any modiﬁ  cation 
of the vector. 
Designing Future Vectors
 It will thus be essential to build a free, 
accessible database incorporating all 
relevant information gathered from 
both experimental and clinical settings. 
In this respect, information gathered 
from the SCID-X1 and adenosine 
deaminase deﬁ  ciency trials is awaited 
with great interest. Combining all 
available information will be the only 
way to determine the frequency of 
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Figure 1. Distribution of MLV and SIV Integration Sites within a 60-kb Window Centered on 
Transcription Start Sites
The vertical arrow points to 0 kb. Each gray bar corresponds to the percentage of SIV 
integration sites within a 5-kb interval, and black bars correspond to the percentages 
of MLV integration sites in a 5-kb interval. The distribution of a set of 65,000 in silico–
generated random integration sites is represented by the dashed line. 
(Source: [9].)PLoS Medicine  |  www.plosmedicine.org 0024
insertions that have a potential to 
induce activation of a protooncogene 
(a risk primarily associated with the 
use of RV) or to induce disruption 
of a regulatory gene (a risk primarily 
associated with the use of LV). Studies 
of relevant gene expression activation 
or suppression should therefore be 
carried out in parallel. 
It is only from these multiple 
analyses, including a careful 
comparison of the oncogenic potential 
of vectors in relevant animal models, 
that a precise assessment of the risk 
associated with use of retroviruses for 
gene therapy will come. These data 
will thus be the basis for objective 
comparison between technologies and 
for the design of safer vectors.  
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